One Day MD | Evidence-Based Wellness

Updated October 2026 Starting a GLP-1-based medication is usually not a matter of taking the highest dose from day one. Most injectable medications used for obesity or diabetes are deliberately started at a low dose and increased gradually. This process is called dose escalation or titration . The reason is straightforward: these medicines affect appetite, stomach emptying, satiety, blood glucose and gastrointestinal function. Starting too aggressively can increase nausea, vomiting, diarrhea, constipation and other adverse effects. FDA-approved labels for semaglutide and tirzepatide specifically use gradual escalation to reduce gastrointestinal adverse reactions. FDA Wegovy Prescribing Information ; FDA Zepbound Prescribing Information . OneDayMD Key Point: Dose escalation is not a race to the maximum dose. The objective is to find a dose that provides an appropriate therapeutic response while remaining tolerable and medically appropriate. Not every patient needs the...

Updated October 3, 2026 GLP-1 therapy has moved far beyond the simple phrase “weight-loss drugs.” Semaglutide, tirzepatide and newer oral and multi-receptor therapies are reshaping obesity, diabetes and cardiometabolic care. But a useful GLP-1 guide needs two columns: what these medicines can do, and what they can cost if treatment is poorly matched, escalated too quickly, or accompanied by inadequate nutrition and physical activity. This GLP-1 manual brings the major evidence together in one place: the drug family, approved 2026 therapies, emerging candidates, expected weight loss, cardiovascular and kidney outcomes, liver and sleep-apnea data, adverse effects, contraindications, oral contraceptive issues, peri-procedural considerations, muscle and bone preservation, monitoring and what happens when treatment is stopped. The central idea: GLP-1 therapy should not be judged by the scale alone. The clinically meaningful goal is better health w...